Preclinical Development Services
In vitro and in vivo methods to provide a study setup that thoroughly determines safety and efficacy
The IND-dossier requires an in-depth profiling and extrapolation of pharmacological parameters to substantiate the proposed clinical dosing-regimen to meet the requirements for the desired exposure in a human subject while minimizing its toxic effects.
It is part of InnoSer’s ambition to serve its customers in all stages of their preclinical research. As such, we are currently in the process of applying for a GLP-accreditation.
Our Approach
Readily available to guide you through the study design process and support you in accelerating your preclinical research
With our wide portfolio of methods and models, we can determine the transferability and reliability of your results supporting you in the transition of your compounds from bench to the clinic. Our team and network of experts are committed to accelerating the drug development process to help you deliver your treatment to patients at a fast pace.
InnoSer can support you in developing your clinical hypothesis by using a pharmacometrics approach. Using tools such as population-based pharmacokinetic modelling (PopPK) we can support you in optimizing your clinical setup for specific substrata of patients.
Contact a development expert and let’s bring your research closer to clinical trials
Our Capabilities
InnoSer is currently expanding its offerings of in vitro models for specialty toxicology, including new approach methods (NAMs), such as genetic toxicity, mutagenicity, carcinogenicity, liver toxicity, cardiotoxicity and neurotoxicity.
In vivo pharmacology
- DMPK properties
- Therapeutic efficacy studies
- Pharmacokinetics
- MTD (Maximum Tolerated Dose) determination
- Dose Response Relations
- Translational disease models
Toxicology
- Single Dose Toxicity
- Repeated Dose Toxicity
- Toxicokinetics
- Medical device biocompatibility
